Press Release Mar 16 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has received final approval from the USFDA for Eluxadoline Tablets, which are indicated for treating irritable bowel syndrome with diarrhea. This approval allows Zydus to manufacture the tablets at its facility in Ahmedabad and grants them eligibility for a period of shared generic drug exclusivity. The press release highlights Zydus's position as one of the first applicants to submit a complete application for these tablets. The filing serves to inform investors and the exchange about this significant regulatory approval.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 14 2025
- Press Release Mar 12 2025
- Press Release Mar 10 2025
- Press Release Mar 05 2025
- Press Release Mar 04 2025
Later from Zydus Lifesciences
- Press Release Mar 18 2025
- Press Release Apr 11 2025
- Press Release Apr 16 2025
- Press Release Apr 17 2025
- ITC Reversal Of Common ITC U/s17(2) Required In Relation To Activity Of Subscription And Redemption Of Mutual Funds
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences